




HEOR



# Health Economics & Outcomes Research Fellowships

2025-2027

 **NOVARTIS** | Reimagining Medicine



# Novartis is a world leader in the research and development of products to protect and improve health and well-being.

Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz. Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing, and marketing prescription drugs to prevent and cure diseases, to ease suffering and to enhance quality of life. Novartis' portfolio of products is directed toward cardiovascular, multiple sclerosis, immunology, hepatology, and dermatology, organ transplantation, ophthalmology, oncology and hematology, and other therapeutic areas.

Novartis, derived from the Latin *novae artes*, meaning "new skills," is committed to using new skills to improve health and well-being through innovative products and services. Recognizing an increasing need for outcomes information, resources and expertise, the Health Economics & Outcomes Research (HEOR) departments at Novartis strive to be best-in-class in the generation of outcomes evidence that demonstrates value and optimizes patient access to Novartis products. This is accomplished through execution of burden and cost-of-illness studies, economic evaluations alongside clinical trials, comparative effectiveness research, cost-effectiveness analyses, prospective observational studies such as effectiveness registries, retrospective claims database analyses and patient-reported outcomes research.







## Purpose

The Health Economics & Outcomes Research (HEOR) Fellowship Program provides training and hands-on experience in a broad range of health economics, outcomes research and comparative effectiveness research (CER) opportunities. This 2-year program is structured to allow the Fellows to gain proficiency in the field of health economics, outcomes research and CER as conducted in academic, managed care, hospital, health policy and/or pharmaceutical industry settings.



## Overview

Novartis Pharmaceuticals Corporation is pleased to offer three 2-year Health Economics & Outcomes Research (HEOR) Fellowship positions for the 2025-2027 cycle.

The objective of the first year is to educate the fellow on general principles and methods applied in health economics and outcomes research. Concurrently, the fellow will participate in ongoing outcomes research projects at the first year fellowship site. All Fellows will spend the second year of the Fellowship at the US-based headquarters of Novartis Pharmaceuticals Corporation located in East Hanover, New Jersey.


While at Novartis, "field-based" training will be undertaken as part of the Fellowship training. Fellows will participate in health economics and outcomes research projects and gain experience in how a pharmaceutical manufacturer uses clinical, economic, and humanistic data to support the development and commercialization of its products, with opportunities in dermatology, cardiovascular franchises and renal franchises.

The fellowship positions differ by first-year site requirements and type of experience offered. Each position is described in this brochure. Compensation includes a competitive stipend, basic medical insurance, holiday and vacation time, plus other benefits associated with each specific academic/managed care institution.

## First-Year Fellowship Sites for 2-Year Programs (3 Positions):

- Baylor Scott & White Health, Temple, TX/  
The University of Texas at Austin, Austin, TX  
(1 position)
- Jefferson College of Population Health,  
Thomas Jefferson University, Philadelphia, PA  
(1 position)
- University of Pittsburgh School of Pharmacy/  
UPMC Health Plan, Pittsburgh, PA  
(1 position)

## Fellowship Alumni: Where Are They Now?



## Contact

Please contact current Fellows for any site-specific questions (contact information provided on subsequent pages).

For inquiries regarding general application or interview process, please contact:

Batul Electricwala, PhD, BPharm  
Director, HE&OR and  
HE&OR Fellowship Director  
East Hanover, NJ  
[usheor.fellowship@novartis.com](mailto:usheor.fellowship@novartis.com)



# Novartis Pharmaceuticals Corporation/ Baylor Scott & White Health/ The University of Texas at Austin



## Fellowship Sites & Preceptors

### Baylor Scott & White Health

Paul Godley, PharmD, FASHP, BCPS, Director of Pharmacy, Ambulatory & Speciality Clinical Pharmacy Services, Temple, TX

### The University of Texas at Austin College of Pharmacy

Chanhyun Park, PhD, MPharm, MEd, RPh, Assistant Professor of Health Outcomes, Austin, TX

### Novartis Pharmaceuticals Corporation

Batul Electricwala, PhD, BPharm, Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

## Baylor Scott & White Health/The University of Texas

Baylor Scott & White is an integrated healthcare system in central Texas. The Scott & White Health Plan is a health maintenance organization that has over 400,000 members and is affiliated with the Baylor Scott & White Quality Alliance, the system's accountable care organization, which represents over 6,000 physicians. Baylor Scott & White is affiliated with the College of Medicine, Texas A&M University Health Science Center, and the College of Pharmacy, The University of Texas at Austin.

The Department of Pharmacy at Baylor Scott & White provides progressive and innovative pharmaceutical services in a variety of environments for all components of the institution. Included are clinical and distributive services for the hospital, clinic and health plan, as well as sponsorship of pharmaceutical care programs and ambulatory care clinics focusing on lipid, diabetes and anticoagulation management. Fellows will gain significant understanding of the key issues involved in pharmacy services provided by prescription benefits management and managed care organizations. The integrated character of the institution and the Department of Pharmacy provides significant opportunities for pharmacy practice, research and education.

The Health Outcomes and Pharmacy Practice Division, College of Pharmacy, The University of Texas at Austin, is one of the preeminent educational institutions for pharmacy education in the nation. The college is located in downtown Austin, and

the Fellow is offered the option of pursuing the Master of Science degree in Pharmaceutical Sciences at the University of Texas, Austin. The degree would be granted at the end of the Fellowship provided that the required coursework and thesis have been completed. The recommended course of study is designed to assist the Fellow in coordinating required and recommended coursework along with the Fellowship requirements.

However, the coursework is tailored based on individual interests, background and career goals. Additionally, the College is home to TxCORE (Texas Center for Health Outcomes Research and Education), which is a leader in addressing population and individual health through innovative, high-quality research, and education, and serves the community by responding to critical health care issues that impact patients' daily lives. TxCORE combines the strengths of its nationally recognized clinical, pharmacy, social and behavioral, economics, and policy researchers to collect, analyze, and interpret data, and disseminate research findings throughout the many sectors of the health care industry, government, and private sector organizations.

The unique nature of the Baylor Scott & White integrated healthcare system, combined with the pharmacoeconomic expertise at the College of Pharmacy, offers significant opportunity for individuals interested in the Novartis Fellowship experience.

### Eligibility

*Eligible candidates must have a doctorate in pharmacy or the combination of an undergraduate degree in pharmacy plus an advanced degree in health services research, public health, health policy, pharmacy, economics, medicine or other related area. Experience in, or at a minimum, exposure to some aspect of outcomes research, health economics or another related field of research is preferred.*

### Information

*For questions or additional information, please contact:*

Raquel (Skyla) Erb, PharmD  
Health Economics & Outcomes Research Fellow  
Email: raquel.erb@bswhealth.org

All questions regarding potential visa sponsorship should be directed to the collaborating institution.





**First-Year Fellow:  
Raquel (Skyla) Erb, PharmD**

Raquel Erb is a first-year Health Economics & Outcomes Research (HEOR) Fellow with Novartis Pharmaceuticals Corporation, Baylor Scott & White Health (BSWH), and the University of Texas at Austin (UT Austin).

Raquel received her Doctor of Pharmacy degree from UT Austin. Her interest in HEOR stems from her background in managed care and community research. During her time at UT Austin, Raquel participated in several research projects in areas such as claims data analysis, literature reviews and quality assessments of HEOR studies. Her research has been presented at various conferences including the Academy of Managed Care Pharmacy (AMCP) and the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).

Prior to the fellowship, Raquel reviewed clinical trial and medical device safety data while completing a rotation with the FDA's Center for Device and Radiological Health. She also completed an AMCP Foundation internship in specialty care in conjunction with Sanofi and Blue Cross NC where she researched patient preferences on new hemophilia therapies. These experiences have deepened her understanding of how HEOR principles are applied in various industries.

During her first year, Raquel will collaborate with pharmaceutical companies to conduct clinical outcome and economics studies at BSWH, while supporting the Antimicrobial Stewardship and the P&T Committee. In addition, Raquel is working towards earning a Master's degree in Pharmaceutical Science from the Division of Health Outcomes and Pharmacy Practice at the University of Texas at Austin.



**Second-Year Fellow:  
Xiaoxia (Summer) Wang, PharmD**

Xiaoxia (Summer) Wang is a second-year Health Economics Outcomes Research (HEOR) Fellow with Baylor Scott and White Health and Novartis Pharmaceutical Corporation.

Summer received her Doctor of Pharmacy degree from the University of South Carolina with a dual degree in Healthcare Informatic Technology. During pharmacy school, Summer started to work on several research projects in the Department of Clinical Outcomes and Pharmacoeconomics, where she had the opportunity to support real-world evidence studies and gain knowledge in Pharmacoeconomics. Before the fellowship, Summer gained exposure to HEOR and market access during her one-year internship at The Kinetix Group, a HEOR consulting company, where she supported landscape analyses and research projects for medical and scientific teams.

During the first year of the fellowship at Baylor Scott and White Health, Summer conducted industry-sponsored studies focused on the patient journey with prurigo nodularis, and wrote proposals for several industry-sponsored projects, including patient-reported outcomes of migraine, prescribing patterns of breast cancer patients, and medication utilization of SLE patients. In addition, Summer led outcomes research projects in obesity treatments and the utilization of SGLT-2 inhibitors in heart failure patients, and she was involved in providing RWE data to the internal antimicrobial stewardship committee.

In her second year at Novartis, Summer supports the US HEOR activities in the Oncology team. She works cross-functionally with internal and external stakeholders, working on various parts of a project from concept development to data dissemination dependent on strategic alignment. She is currently involved in multiple projects, including a retrospective claims analysis, patient preference study, and strategic preparation for launch. Additionally, Summer is concurrently pursuing her master's in healthcare outcomes at the University of Texas at Austin.

## Novartis Pharmaceuticals Corporation/ Thomas Jefferson University, Jefferson College of Population Health



### Fellowship Sites & Preceptors

#### Thomas Jefferson University

Vittorio Maio, PharmD, MS, MSPH, Professor and Director, Health Economics and Outcomes Research Fellowship, Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA

#### Novartis Pharmaceuticals Corporation

Batul Electricwala, PhD, BPharm, Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

### College of Population Health, Thomas Jefferson University

Established in 2008, the Jefferson College of Population Health (JCPH) is one of six colleges that comprise Thomas Jefferson University, founded in 1824 as Jefferson Medical College. JCPH builds upon the 18-year history of Jefferson's Department of Health Policy and specializes in all key areas of population health—public health, health policy, healthcare quality and safety, and applied health economics and outcomes research (AHEOR). The College has one of the oldest and most established outcomes research Fellowship programs in the country. To date, over 50 individuals have completed JCPH Fellowships and have successfully pursued careers in all sectors of the healthcare industry, including government, pharmacy, insurers and consulting.

During the first year, the Fellow will work in JCPH at the University's Philadelphia Center City campus and be assigned to manage specific outcomes research projects. As a member of the JCPH research team, s/he has the opportunity to attend and present at research meetings, journal clubs, Population Health Forums and sponsored educational programs. S/he may also contribute to any one of several graduate level classes taught by JCPH faculty in the College's public health, AHEOR, health policy, healthcare quality and safety, population health intelligence and population health graduate programs. The Fellow will develop writing skills through completion of a writing seminar, peer review of continuing education articles and authorship of manuscripts for publications edited by American Journal of Medical Quality, Population Health Management, and Population Health Matters.

Networking is also an important activity during the first year. The Fellow will interact with decision makers from both within the University and from a broad variety of organizations, including pharmaceutical and device manufacturers, health plans and other health-related employers. The Fellow will regularly meet with JCPH faculty and staff to discuss research projects and academic experiences, and s/he will be assigned a faculty mentor to coach him/her during the first year. Completion of master's level coursework through JCPH is a formal component of this Fellowship and serves to develop the knowledge and skills required for health economics and outcomes research. The Fellow has the option to complete a fully supported graduate Certificate or Master of Science degree program in public health, population health, population health intelligence, health policy or applied health economics and outcomes research.

The second year of training will take place at Novartis, located in East Hanover, New Jersey. During this time, under the guidance of a Novartis preceptor, the Fellow will work directly with the HEOR department at Novartis for a period of one year in order to further their educational objectives by gaining applied experience in health economics and outcomes research. In addition to project work, the Fellow will participate in meetings to share his or her work and further develop networking and presentation skills.

#### Eligibility

*Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy, pharmacy administration or a related discipline. A background in pharmacy or medicine and experience in outcomes research, health economics or another related field of research is preferred. Candidates must have excellent written and verbal communication skills.*

#### Information

*For questions or additional information, please contact:*

Mumbi Kimani, PhD  
Health Economics & Outcomes Research Fellow  
Email: [mumbi.kimani@jefferson.edu](mailto:mumbi.kimani@jefferson.edu)

All questions regarding potential visa sponsorship should be directed to the collaborating institution.





### **First-Year Fellow: Mumbi Kimani, PhD**

Mumbi Kimani is a first-year Health Economics & Outcomes Research (HEOR) Fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceuticals Corporation.

Mumbi is a Health Economist with a PhD in Economics from the University of Cape Town, who previously served as a faculty member at Penn State University. Her interest in HEOR was sparked by policy discussions and challenges surrounding US healthcare reforms, and her own research on COVID-19's impact on vulnerable populations. Mumbi's work has been published in prestigious journals such as JAMA Network Open and PLOS ONE. Recognizing the growing demand for specialized skills in health economics, she completed a "Modelling Cost-Effectiveness in Healthcare" course at the London School of Economics, to enhance her proficiency in healthcare-related mathematical and simulation modeling.

During her first year at JCPH, Mumbi will be involved in diverse projects, including manuscript and commentary writing, and she will also develop research questions and models for various diseases, such as renal cancer, using datasets like claims and registry data. Additionally, she plans to pursue an MS degree in Applied Health Economics and Outcomes Research. Throughout the fellowship, Mumbi will leverage her expertise to improve healthcare outcomes and bring a wealth of transferable skills, along with a strong dedication to advancing the effectiveness and efficiency of healthcare systems through rigorous economic analysis and innovative research.



### **Second-Year Fellow: Charlene Tugwete, PharmD**

Charlene is a second-year Health Economics & Outcomes Research (HEOR) Fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceuticals Corporation.

Charlene received her Doctor of Pharmacy from the University of Maryland School of Pharmacy. She began her journey into health economics & outcomes research (HEOR) at the University of Maryland's Pharmaceutical Health Services Research department. Her initial project analyzed Z-code utilization among oncology patients, aiming to uncover correlations between social determinants of health (SDOH) and healthcare usage using private payer claims. At the Jefferson College of Population Health (JCPH), Charlene has led various outcomes research initiatives, including a scoping review on cost-effectiveness analyses of immune checkpoint inhibitors in renal cell carcinoma, descriptive analyses of statin utilization in clinical atherosclerotic cardiovascular disease (ASCVD) patients, and investigations into prescribing patterns of SGLT2i utilization in heart failure patients. In addition, she has also contributed to understanding state level public reporting on C. difficile infection rates and conducted a retrospective cohort study on lung cancer screening in commercially insured patients. As a result, she presented at 4 research posters at conferences including AMCP and ISPOR.

During her second year of her fellowship at Novartis, Charlene supports US HEOR Immunology team by overseeing research studies and working with various cross-function teams in concept development, protocol evaluation, and strategic planning. Her research activities include qualitative research, economic modeling and retrospective claims database analyses. Charlene is also working on her Master of Science in Applied HEOR at JCPH.

## Novartis Pharmaceuticals Corporation/ University of Pittsburgh School of Pharmacy/ UPMC Health Plan (1 position)



### Fellowship Sites & Preceptors

#### University of Pittsburgh School of Pharmacy

Kangho Suh, PharmD, PhD, Assistant Professor, Department of Pharmacy & Therapeutics, Pittsburgh, PA

#### UPMC Health Plan

Chester "Bernie" Good, MD, MPH, Senior Medical Director, Center for Value-Based Pharmacy Initiatives, Pittsburgh, PA

Samuel Peasah, PhD, RPh, MBA, Director, Center for Value-Based Pharmacy Initiatives and Associate, Adjunct Associate Professor, University of Pittsburgh School of Pharmacy, Pittsburgh, PA

#### Novartis Pharmaceuticals Corporation

Batul Electricwala, PhD, BPharm, Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

### The University of Pittsburgh School of Pharmacy/UPMC Health PlanUPMC

UPMC Health Plan, headquartered in Pittsburgh, Pennsylvania, is among the nation's fastest-growing health plans. It is owned by the University of Pittsburgh Medical Center (UPMC), a world-renowned integrated health care delivery and financing system. The UPMC Health Plan is committed to providing its members better health, through an evidence-based insurance design and generous pharmacy benefit. The Center for High-Value Healthcare (CHVHC) is a nonprofit research organization housed within UPMC Health Plan that translates, through research and collaboration, the work of the UPMC Insurance services into evidence-based practice and policy change. The Center for Value-based Pharmacy Initiatives is a center within CHVHC that focuses on value/outcomes-based contracts and pharmacy-related outcomes research in collaboration with the pharmacy department of the Health Plan and other external partners..

University of Pittsburgh is one of the oldest institutions of higher education in the United States. It was ranked as the No. 1 public university in the Northeastern United States in 2020 and is ranked in the top 20 among the nation's top public colleges and universities. At the School of Pharmacy, the Fellow will have the opportunity to earn an online Master of Science in PharmacoAnalytics – Pharmaceutical Outcomes Research. This program provides students with tools and skills necessary to analyze large, healthcare datasets and apply data analytic and pharmacoepidemiology concepts to enhance pharmaceutical use and outcomes. A key feature of this program is competency-based learning, which requires students to demonstrate application of didactic learning through hands-on analysis of real-world data and evidence. Students will develop core competencies related to study design, data collection, data management, data organization, data analysis, and data visualization/communication.

The intersection of managed care, academia, and opportunities to lead outcomes research projects will enable the Pitt Pharmacy and UPMC Health Plan 1st year site to equip the fellow with the necessary skills and abilities to succeed in the 2nd year at Novartis and beyond.

#### Eligibility

*Eligible candidates must have a doctorate in pharmacy. Experience in, or at a minimum, exposure to some aspect of outcomes research, health economics or another related field of research is preferred.*

#### Information

*For questions or additional information, please contact:*

Cindy Chan, PharmD  
Health Economics & Outcomes Research Fellow  
Email: CMC392@pitt.edu

All questions regarding potential visa sponsorship should be directed to the collaborating institution.





**First-Year Fellow:  
Cindy Chan, PharmD**

Cindy is a first-year Health Economics & Outcomes Research (HEOR) fellow with Novartis Pharmaceutical Corporation, the University of Pittsburgh, and University of Pittsburgh Medical Center (UPMC) Health Plan.

Cindy received her Doctor of Pharmacy and Master of Health Informatics degrees from the University of Minnesota. Her interest in HEOR stemmed from her managed care experiences with population health management as well as oncology patient care experience, where witnessing the impact of drug toxicities on patients' quality of life motivated her to learn how value of drug therapies is evaluated with health economic and outcomes evidence.

Prior to the fellowship, Cindy interned with Blue Cross and Blue Shield of Minnesota, where she analyzed pharmacy and medical claims data to investigate the impact of formulary strategy on cost and utilization patterns. Her achievement of winning National Third Place in the AMCP P&T Competition in 2023 deepened her interest in economic modeling and cost-effectiveness analyses. In her rotation with Eli Lilly's Value, Evidence, and Outcomes team, she gained valuable insights into pharmaceutical value-based contracting and value drivers in field HEOR teams' interactions with payers. She also supported market research, new business development, and cost estimation projects during her rotation with Cencora's Value and Access Strategy team.

During her first year, Cindy will be involved in administrative claims data analysis, manuscript writing, development of value-based contract concepts, cost analysis, and economic modeling in various research projects at the University of Pittsburgh and UPMC Health Plan's Center for High-Value Health Care (CHVHC). Alongside these projects, she is pursuing a master's degree in PharmacoAnalytics - Pharmaceutical Outcomes Research. Cindy looks forward to expanding her HEOR knowledge through a unique blend of managed care, academic, and industry experiences in her fellowship.



**Assistant Professor:  
Kangho Suh, PharmD, PhD**

Kangho Suh is an Assistant Professor in the Department of Pharmacy & Therapeutics in the School of Pharmacy at University of Pittsburgh. His research areas are in pharmacoepidemiology, health economics, and outcomes research. He received his PharmD from Rutgers University and then completed the Novartis HEOR fellowship at University of Texas at Austin (where he received his MS) and Scott & White Health Plan. Afterwards, he graduated with his PhD from the CHOICE Institute at University of Washington. As a previous fellow, Kangho looks forward to mentoring and growing the next generation of HEOR leaders at Pitt through the Novartis fellowship.

Kangho's research includes assessing outcomes in drug-associated acute kidney injury, examining comparative and cost-effectiveness in second generation antipsychotics long acting injectables, and evaluating healthcare costs in chronic kidney disease. Additionally, he leads research projects for the Rx Center for Outcomes Research and Practice Implementation Excellence (RxCore) between Pitt Pharmacy and UPMC with the help of graduate students. Furthermore, he is an external member of the Institute for Clinical and Economic Review where he developed the economic models in Amyotrophic Lateral Sclerosis, nonalcoholic steatohepatitis, and currently Metachromatic Leukodystrophy.



**Senior Medical Director:  
Chester “Bernie” Good, MD, MPH**

Bernie Good is the Senior Medical Director for the Center for Value-Based Pharmacy Initiatives with UPMC Health Plan, where he provides oversight for the development, implementation, and evaluation of innovative value-based payment models for pharmaceuticals. He is also a Professor of Medicine and Pharmacy at the University of Pittsburgh where he has mentored students, residents, and fellows. He received his medical degree from George Washington University and completed an internal medicine residency at University of Pittsburgh. Prior to UPMC, he worked as a staff physician and national leader in Veterans Affairs Pharmacy Practice and Policy for 18 years, where he contributed to several research and quality improvement initiatives. He also served as technical advisor for several national organizations including CMS, FDA, and US Pharmacopeia.



**Director:  
Samuel Peasah, PhD, RPh, MBA**

Samuel Peasah is a Director at the Center for Value-Based Pharmacy Initiatives, UPMC Health Plan and an Adjunct Associate Professor at University of Pittsburgh School of Pharmacy. He received his MBA and PhD from University of Florida, and he is a fellow of the CDC Prevention Effectiveness Fellowship—a post-doctoral fellowship in health economics. He has expertise in value-based contract negotiations, implementation, assessment, and reporting, and other quality-of care outcomes evaluation at UPMC Health Plan. Prior to his position at UPMC, he was faculty, director for the Center for Outcomes Research and Education, and director of post-graduate pharmaceutical fellowships at Mercer University College of Pharmacy in Atlanta Georgia. He has precepted and published with pharmacy students and residents at Mercer and continues to precept Pitt School of Pharmacy PharmD students and residents in health outcomes research.



## Previous Fellows

### Neetu Agashivala, MS

Global RWE Head, Cardiovascular Renal Metabolism,  
Novartis

### Adaeze Amaefule, PharmD

HEOR Lead, Oncology  
Astellas Pharma

### Lauren Bartolome, PharmD

Director, HEOR I&I,  
Pfizer, Inc.

### Kelly Fee Bell, PharmD, MSPH

Value Evidence Lead,  
GlaxoSmithKline

### William Boyko, PharmD

Pharmacist Consultant,  
P&C Pharma

### Cat Bui, PharmD, PhD

Director, HEOR, Hematology,  
AbbVie

### Scott Bull, PharmD

Director, Clinical Development,  
Johnson & Johnson

### Beilei Cai, PhD, MA

Senior Director, US HEOR-Oncology,  
Novartis

### Aaron Carabajal-Johnson, PharmD, MS

Senior Manager, HEOR  
Inovalon

### Jane Chang, MPH

Senior Director, Value and Evidence,  
Pfizer, Inc.

### Michelle Choi, PharmD

Medical Science Liaison-Immunology,  
Sanofi

### Paul C. Cockrum, PharmD, DPH

North America Director, Oncology HEOR,  
Ipsen Biopharma

### Arijita Deb, PhD

Director, Value Evidence and Outcomes,  
GlaxoSmithKline

### Laurence Djatche, PharmD, MS

Director, HEOR,  
Endo Pharmaceuticals

### QuynhChau Doan, PhD, MS, RPh

Director, External Strategies HEOR,  
AbbVie

### Joseph Doyle, MBA

Pharmacy Manager,  
Dr. G's Pharmacy

### Batul Electricwala, PhD

Director, HEOR,  
Novartis

### John Fastenau, PhD, MPH, RPh

Senior Director, Patient Reported Outcomes,  
Janssen Pharmaceuticals

### Feride Frech, PhD, MPH

Senior Director, HEOR & RWE,  
Eisai, Inc.

### Rahul Garg, PhD

Assistant Professor,  
Chicago State University

### Joseph Goble, PharmD, MS

Director, Value & Evidence Scientific Engagement - Field,  
Janssen Pharmaceuticals

### Boris Gorsh, PharmD, MS

Value Evidence Leader,  
GlaxoSmithKline

### Bill Grant, PhD

Associate Professor of Economics, College of Business,  
James Madison University

### Amy Grogg, PharmD

Strategic Advisor,  
Vesey Street Capital Partners

### Kristy Hanson, PharmD, MS

Scientific Consultant, Value Demonstration,  
United BioSource Corporation:  
An Express Scripts Company

### Peter Hur, PharmD, MBA

Director, Worldwide HEOR Inflammation and Immunology,  
Pfizer, Inc.

### Archi Jackson, PharmD

President,  
A&S Healthcare Consulting and Analytics, Inc.

### Tom Karagiannis, PharmD, MS

Director, Global Market Access and Pricing,  
AbbVie

### Jennifer Kim, PharmD

Director, Global Pricing and Market Access,  
AstraZeneca

### John Kim, PharmD

Executive Director, Head of Global Market Access,  
Seagen

### Nina Kim, PharmD, MS

Associate Director, Real World Value & Evidence, Oncology,  
Janssen Pharmaceuticals

### Yoona Kim, PharmD, PhD

Co-founder and CEO,  
Arine

**John Ko, PharmD, MS**

Senior Director, Value, Evidence & Development Strategy,  
Beam

**Amy Law, PharmD, MS**

Director, HEOR,  
Pfizer, Inc.

**Junji Lin, PhD**

Associate Director,  
Jazz Pharmaceuticals

**Jackie Lu, PharmD, MS**

Executive Director of Marketing,  
Pacira Pharmaceuticals

**Mario Luong, PharmD, MPH**

Director of Operations,  
Optum

**Geneen Graber Maxwell, PharmD**

President and CEO,  
Dr. G's Pharmacy

**Shilpa Mehta, PharmD**

Head of Oncology Marketing - Asia Pacific,  
Merck & Co, Inc

**Patrick Mends, PharmD**

Director, Content Development and Training,  
Sandoz

**Laetitia N'Dri, PharmD**

Senior Manager US HEOR,  
Bristol Myers Squibb

**Gilbert C. Ngan, PharmD**

Pharmacist: Part D Benefits Analyst,  
CMS

**Cindy Nguyen, PharmD**

Senior Associate Director, HEOR Value Evidence and  
Outcomes Liaison,  
Boehringer Ingelheim

**Jennifer Nguyen, PharmD**

Senior Manager, HEOR US Oncology  
Novartis

**Lina Nol-Heiring, BS, MBA**

Therapeutics Sales Specialist,  
LEO Pharma

**Grace Oh, PharmD**

Associate Director, WW Scientific Content and US Market  
Capabilities, Thoracic and Emerging Tumors,  
Bristol Myers Squibb

**Engels Obi, PhD**

Director, Global Outcomes Research and Value Evidence Strategy  
Team Lead,  
Merck

**Jacqueline B. Palmer, PharmD, MBA**

Director, Professional Promotions Marketing,

Novartis

**Jina Park, PharmD**

Director, Advanced Analytics,  
Komodo Health

**Siyeon Natalie Park, PharmD**

Enterprise Pharmacy - Clinical Carepath,  
Geisinger

**Shivangi Patel, PharmD**

Senior Manager, Patient-Centered Outcomes Research,  
Global Market Access,  
Sarepta Therapeutics

**Hoa T. Pham, PharmD**

Senior Director, Field HEOR,  
Beigene

**Ngan Pham, PharmD**

Senior Consultant,  
IQVIA

**Craig Plauschinat, PharmD, MPH**

Director, HEOR & RWE,  
Eisai, Inc.

**Shibani Pokras, MPH**

Senior Director, Oncology Cell Therapy,  
GlaxoSmithKline

**Karim Prasla, PharmD, MS**

VP, Clinical Outcomes Advanced Analytics and Research,  
Magellan Health Services

**Karina Raimundo, BS Pharmacy, MS**

Director, HEOR,  
Genentech, Inc.

**Swetha Raparla, MS**

Analytics Consultant,  
Cigna

**David Ray, PharmD, MBA, MPH**

Executive Director, Global HEOR,  
Karyopharm Therapeutics, Inc.

**Seon Young Ryu, PharmD**

Mom/Independent Consulting,  
Previously at Genentech

**Rahul Sasané, PhD, MS, BPharm**

Head - Global HEOR-RWE & Reimbursement,  
Cerevel Therapeutics, LLC

**Veronica Sendersky, PharmD**

Managing Director,  
Excellentia Pharma Consulting

**Amishi Shah**

Associate Director, Oncology Digital Engagement &  
Channel Strategy,  
Merck



**Hemal Shah, PharmD**

President/Founder,  
Value Matters, LLC

**Karisha Shelley, PharmD**

Associate Director, HEOR - US Market, Oncology,  
Bristol Myers Squibb

**Slaven Sikirica, MS**

Senior Director,  
Lexicon Pharmaceuticals, Inc.

**Anh Singhania, PharmD**

Senior Director, Health Systems & Outcomes, Medical Affairs  
Intercept Pharmaceuticals

**Liz Stanley Smart, MPH**

Senior Associate Director, HEOR,  
Boehringer Ingelheim

**Bhavini Patel Srivastava, MS, BS Pharmacy**

Director, HEOR,  
AbbVie

**Kangho Suh, PharmD, PhD, MS**

Assistant Professor,  
University of Pittsburgh

**Dusica Tasic, MS, BS Pharmacy**

Health Economics Manager, Global Marketing,  
GE Healthcare

**Devi Thaker, PharmD, MS**

Director, PharmacoAnalytics,  
Express Scripts

**Karishma Thakkar, PharmD**

Senior Manager, HEOR Product Lead  
Novartis

**Ryan Thaliffdeen, PharmD,**

MS Senior Manager,  
Global Value & Access Gilead

**Melody Tran, PharmD, MS**

Medical Outcomes Liaison,  
Abbott Laboratories

**Yuen Tsang, PharmD, MPH**

Associate Director, Real World Value & Evidence,  
Janssen Pharmaceuticals

**Stuart Turner, MPH**

Executive Director Global Real World Evidence &  
Data Science - Solid Tumors,  
Novartis

**Stefan Varga, PharmD, MSc**

Director, WW HEOR,  
Bristol Myers Squibb

**Ashok Vegesna, PharmD, MS**

Director, National Accounts (Central US),  
Novartis

**Joel Wallace, PharmD, MPH, MBA**

Head, Global HEOR, Market Access and Business Strategy,  
Exelixis

**Alexandra Wallem, PharmD,**

Associate Director, Outcomes Liaison,  
Eli Lilly

**Pin Xiang, PharmD**

Director of HEOR Value Demonstration - CNS,  
Boehringer Ingelheim

**Esther Yi, PharmD, MS**

Director, Value & Evidence Inflammation and Immunology  
Pfizer

**Krista Yokoyama, PharmD**

Senior Manager, Pharmacy Analytics,  
Blue Shield of California

**Jing Yuan, PhD**

Associate Professor,  
Fudan University

# HEOR Fellowship Application Form

Please type or print

Date: \_\_\_\_\_

Name: \_\_\_\_\_

Last

First

MI

Address: \_\_\_\_\_

Street

City

State

Zip Code

Phone: \_\_\_\_\_

Primary

Secondary

Email: \_\_\_\_\_

**Undergraduate and Graduate Degree(s) (date received or expected):**

\_\_\_\_\_  
\_\_\_\_\_

**2-Year Programs (Preferred Degrees: PharmD, PhD, MS)**

Please rank and check any site(s) of interest:

\_\_\_\_\_ Baylor Scott & White Health/The University of Texas at Austin/Novartis Pharmaceuticals Corporation

\_\_\_\_\_ Thomas Jefferson University College of Population Health/Novartis Pharmaceuticals Corporation

\_\_\_\_\_ University of Pittsburgh School of Pharmacy/UPMC Health Plan/Novartis Pharmaceuticals Corporation

**Application Process (rolling submission, application deadline is October 25th, 2024 at 11:59 pm EDT):**

To apply, please email [usheor.fellowship@novartis.com](mailto:usheor.fellowship@novartis.com) and include the following materials:

- Cover Letter
- Application form with first-year fellowship site(s) preference
- CV
- Email of 2 References

If offered an interview, the following documents will be requested:

- 2 Letters of Recommendation (sent via email from references)
- Unofficial Transcript

**Requirements:**

Graduate degree in a relevant discipline focused on pharmacy, health services research, health economics, epidemiology, or a related discipline (e.g., PharmD, PhD, MPH, etc.). A background in pharmacy or medicine and experience in outcomes research, health economics, or another related field of research is preferred. Excellent communication skills (oral and written). Demonstrated success in working in teams and independently.

**Please email or send the required application materials to:**

Batul Electricwala, PhD, BPharm  
Director, HE&OR and HE&OR Fellowship Director  
Email: [usheor.fellowship@novartis.com](mailto:usheor.fellowship@novartis.com)

